ALLMedicine™ HER2+ Center

Feb 26th, 2021 - We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer (BC). The PAM50-based chemo-endocrine score (CES) predicts chemo-endocrine sensitivity in HR+/HER2-neg...

Feb 25th, 2021 - New strategies for cancer immunotherapy are needed since most solid tumors do not respond to current approaches. Here we used epithelial cell adhesion molecule EpCAM (a tumor-associated antigen highly expressed on common epithelial cancers and the...

Feb 23rd, 2021 - Obesity at breast cancer (BC) diagnosis has been associated with poor outcome, although the magnitude of effect in different BC subtypes is uncertain. We report on the association of obesity/overweight at diagnosis of non-metastatic BC with diseas...

Feb 16th, 2021 - Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resistant H...

Feb 16th, 2021 - Anti-HER2 therapy delivered in the adjuvant setting for breast cancer is given in conjunction with cytotoxic chemotherapy. For HER2-positive (HER2+) patients who cannot tolerate chemotherapy, there is no randomized data regarding the role of anti-...

May 30th, 2020 - The combination of pyrotinib and capecitabine significantly prolonged progression-free survival (PFS), when compared with lapatinib and capecitabine, among patients with previously treated HER2-positive metastatic breast cancer in a phase 3 trial.

May 30th, 2020 - Pyrotinib plus capecitabine achieved a better progression-free survival (PFS) than lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and chemotherapy. Results fro...

May 29th, 2020 - Anthracyclines add toxicity with no evidence of improved survival in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy regimen plus dual HER2 blockade, results of a randomized phase 3 trial have suggested.

May 29th, 2020 - In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, add-on tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.

May 29th, 2020 - Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki (Enhertu) revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer (CRC) and advanced gastric or gastroesophageal junction (GE...

Feb 26th, 2021 - We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer (BC). The PAM50-based chemo-endocrine score (CES) predicts chemo-endocrine sensitivity in HR+/HER2-neg...

Feb 25th, 2021 - New strategies for cancer immunotherapy are needed since most solid tumors do not respond to current approaches. Here we used epithelial cell adhesion molecule EpCAM (a tumor-associated antigen highly expressed on common epithelial cancers and the...

Feb 23rd, 2021 - Obesity at breast cancer (BC) diagnosis has been associated with poor outcome, although the magnitude of effect in different BC subtypes is uncertain. We report on the association of obesity/overweight at diagnosis of non-metastatic BC with diseas...

Feb 16th, 2021 - Androgen receptor (AR) expression occurs in up to 86% of human epidermal growth factor receptor 2-positive (HER2+) breast cancers. In vitro, AR inhibitors enhance antitumor activity of trastuzumab, an anti-HER2 antibody, in trastuzumab-resistant H...

Feb 16th, 2021 - Anti-HER2 therapy delivered in the adjuvant setting for breast cancer is given in conjunction with cytotoxic chemotherapy. For HER2-positive (HER2+) patients who cannot tolerate chemotherapy, there is no randomized data regarding the role of anti-...

Jan 6th, 2021 - This transcript has been edited for clarity. Happy holidays, everyone. This is Dr Kathy Miller from Indiana University. I want to make sure you've had a chance to think carefully about the margetuximab approval by the US Food and Drug Administrati...

Dec 16th, 2020 - A new monoclonal antibody that targets HER2+ in breast cancer, margetuximab-cmkb (Margenza), has been approved by the Food and Drug Administration (FDA). The new drug is indicated for use in combination with chemotherapy for the treatment of patie...

Oct 20th, 2020 - A pathologic complete response (pCR) to targeted therapy in HER2-positive breast cancer portends good long-term outcomes, according to final results of the phase 3 NeoALTTO/BIG 1-06 trial. In fact, for the majority of women, pCR appears to be a ma...

Oct 20th, 2020 - A pathologic complete response (pCR) to targeted therapy in HER2-positive breast cancer portends good long-term outcomes, according to final results of the phase 3 NeoALTTO/BIG 1-06 trial. In fact, for the majority of women, pCR appears to be a ma...

Sep 13th, 2020 - According to the NCCN Breast Cancer Clinical Practice Guidelines for the management of invasive breast cancer, pertuzumab plus trastuzumab plus a taxane is a preferred systemic therapy regimen for recurrent or stage IV HER2+ breast cancer (Categor...